全文获取类型
收费全文 | 2236篇 |
免费 | 783篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 19篇 |
儿科学 | 141篇 |
妇产科学 | 14篇 |
基础医学 | 53篇 |
口腔科学 | 16篇 |
临床医学 | 805篇 |
内科学 | 958篇 |
皮肤病学 | 48篇 |
神经病学 | 129篇 |
特种医学 | 21篇 |
外科学 | 174篇 |
综合类 | 3篇 |
预防医学 | 337篇 |
眼科学 | 14篇 |
药学 | 82篇 |
肿瘤学 | 226篇 |
出版年
2024年 | 25篇 |
2023年 | 151篇 |
2022年 | 95篇 |
2021年 | 102篇 |
2020年 | 200篇 |
2019年 | 63篇 |
2018年 | 204篇 |
2017年 | 202篇 |
2016年 | 205篇 |
2015年 | 196篇 |
2014年 | 228篇 |
2013年 | 224篇 |
2012年 | 75篇 |
2011年 | 62篇 |
2010年 | 148篇 |
2009年 | 229篇 |
2008年 | 65篇 |
2007年 | 40篇 |
2006年 | 53篇 |
2005年 | 62篇 |
2004年 | 40篇 |
2003年 | 35篇 |
2002年 | 21篇 |
2001年 | 32篇 |
2000年 | 37篇 |
1999年 | 40篇 |
1998年 | 33篇 |
1997年 | 25篇 |
1996年 | 28篇 |
1995年 | 29篇 |
1994年 | 16篇 |
1993年 | 17篇 |
1992年 | 9篇 |
1991年 | 6篇 |
1990年 | 7篇 |
1989年 | 5篇 |
1988年 | 4篇 |
1987年 | 9篇 |
1986年 | 4篇 |
1985年 | 4篇 |
1984年 | 2篇 |
1983年 | 5篇 |
1982年 | 2篇 |
1979年 | 1篇 |
排序方式: 共有3040条查询结果,搜索用时 0 毫秒
1.
2.
3.
What Is Sufficient Evidence for the Reliability and Validity of Patient-Reported Outcome Measures? 总被引:1,自引:0,他引:1
4.
Leon´ Adriana Souza-Barbosa PharmD ; S´lvia E. Ferreira-Melo PharmD ; Samira Ubaid-Girioli PharmD ; Eduardo Arantes Nogueira MD PhD ;Juan Carlos Yugar-Toledo MD PhD ;Heitor Moreno Jr MD PhD; 《Journal of clinical hypertension (Greenwich, Conn.)》2006,8(11):803-811
It is unclear whether single and combined pharmacologic inhibition of the renin-angiotensin-aldosterone system have similar effects on endothelial function and blood pressure (BP). The authors evaluated 63 hypertensive patients divided into 4 groups (hydrochlorothiazide 25 mg/d; irbesartan [IRBE] 150 mg/d; quinapril [QUIN] 20 mg/d; or IRBE 150 mg/d + QUIN 20 mg/d) and 25 healthy normotensive subjects (normal) followed for 12 weeks. Endothelium-dependent dysfunction measured as flow-mediated dilation at Weeks 0 and 12 were: normal, 11.5%±2.4% vs 13.5%±2.0%; hydrochlorothiazide, 7.3%±2.0% vs 12.8%±3.1%; QUIN, 7.2%±2.8% vs 13.2%±2.1%; IRBE, 7.1%±2.8% vs 13.0%±2.9%; and IRBE + QUIN, 7.5%±1.9% vs 12.8%±3.0%. Nitroglycerin-mediated responses were: normal, 26.0%±1.9% vs 24.0%±2.5%; hydrochlorothiazide, 17.0%±2.2% vs 18.3%±2.6%; QUIN, 17.8%±3.2% vs 23.4%±3.0%; IRBE, 16.8%±3.6% vs 24.7%±2.0%; and IRBE + QUIN, 17.3%±3.0% vs 25.1%±2.5%. Antihypertensive therapy restored BP to normal and improved the endothelium-dependent and -independent dysfunction after renin-angiotensin-aldosterone system blockade. In a further finding, the combined effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade was not superior to the action of either of these treatments separately. 相似文献
5.
M. C. Robson MD a ; L. G. Phillip MD ; D. M. Cooper RN PhD a ; W. G. Lyle MD ; L. E. Robson RN MS ; L. Odom RN ; D. P. Hill PharmD ; A. F. Hanham MD ; G. A. Ksander MS 《Wound repair and regeneration》1995,3(2):157-167
Transforming growth factor-beta(2) promotes healing in a variety of animal models and exhibits clinical effects thought to be mediated by connective tissue formation. Two clinical trials were conducted to evaluate the safety and effect of transforming growth factor-beta(2) purified from bovine bone and delivered topically to venous stasis ulcers three times per week for up to 6 weeks by means of a lyophilized collagen vehicle. The first was an open-label trial comparing transforming growth factor-beta(2) purified from bovine bone (0.5 microg/cm(2)) with a placebo consisting of lyophilized collagen vehicle-without active drug. After no safety issues arose in that trial, a prospectively randomized, closed-label, observer-blinded, three-armed trial was conducted to compare bovine transforming growth factor-beta(2) (2.5 microg/cm(2)) with the collagen matrix placebo vehicle and with a standard dressing. Standardized elastic compression was applied to all test extremities. The rate of reduction of ulcer area as measured by planimetry was the primary measure of effect. No serious safety-related events occurred in either trial. Clinical evaluation suggested that improvement in the quality and quantity of granulation tissue appeared to precede epithelialization of ulcers treated with bovine transforming growth factor-beta(2). In both studies, treatment with bovine transforming growth factor-beta(2) appeared to have a positive effect on the rate of ulcer closure, whereas ulcers in the control groups continued to exhibit impaired healing. In the open-label study, the mean rate of closure of ulcers treated with bovine transforming growth factor-beta(2) was significantly greater than that of ulcers treated with placebo. There was likewise enhanced reduction in ulcer area in the ulcers treated with bovine transforming growth factor-beta(2) in the second trial. However, because of a higher variability in patient response and a greater placebo effect, the difference was not significant. The placebo was not worse than the standard care arm, thereby showing that the vehicle is not injurious to healing. The combined results of the two trials suggest that, at doses of 0.5 to 2.5 microg/cm(2), bovine transforming growth factor-beta(2) is safe as a topically applied agent in a collagen matrix vehicle and can have a positive effect on closure of venous stasis ulcers. Large multicenter trials appear to be indicated to evaluate fully the potential utility of transforming growth factor-beta(2) in accelerating closure of chronic dermal ulcers. 相似文献
6.
Karissa Y. Kim PharmD CACP ; Kelly Epplen PharmD CACP ; Farzin Foruhari MD ; Hattie Alexandropoulos PharmD 《Progress in cardiovascular nursing》2006,21(2):1-4
A 79-year-old man with a history of deep vein thrombosis and pulmonary embolism received anticoagulation therapy with warfarin 5 mg daily for 8 months. He was diagnosed with osteomyelitis and underwent partial metatarsal resection of his right foot. After surgery, antibiotics were initiated including ertapenem sodium 1 g intravenously every 24 hours, vancomycin 1400 mg intravenously every 24 hours, and rifampin 300 mg by mouth twice daily. Achieving a therapeutic level of anticoagulation was difficult despite escalating doses of warfarin, because of the interaction with rifampin. A 5- to 6-fold increase in warfarin dose was prescribed to reach therapeutic international normalized ratios (INRs), but even these increases were insufficient to maintain his INR in the therapeutic range. After rifampin was discontinued, warfarin doses were gradually reduced over the next 2 months. When concurrent warfarin-rifampin therapy is necessary, vigilant monitoring is imperative and significant increases in warfarin doses are likely. 相似文献
7.
Solish Nowell MD Benohanian Antranik MD Jonathan W. Kowalski PharmD MS on Behalf of the Canadian Dermatology Study Group on Health-Related Quality of Life in Primary Axillary Hyperhidrosis 《Dermatologic surgery》2005,31(4):405-413
BACKGROUND: Patients with primary axillary hyperhidrosis experience substantial functional impairment and reduced health-related quality of life (HRQOL). Few studies have comprehensively evaluated the effects of botulinum toxin type A (BoNT-A) on these symptoms. OBJECTIVE: To prospectively assess the effects of BoNT-A on functional impairment associated with primary axillary hyperhidrosis. METHODS: Patients treated with BoNT-A 50 U per axilla at baseline were assessed 4 and 12 weeks later. Outcome measures included functional impairment as assessed by the Hyperhidrosis Disease Severity Scale and the Hyperhidrosis Impact Questionnaire and dermatology-specific HRQOL as assessed by the Dermatology Life Quality Index. RESULTS: At weeks 4 and 12 after BoNT-A treatment, 85% and 90% of patients achieved the a priori definition of treatment responder. Patients reported less occupational and emotional impairment, spent less time managing their hyperhidrosis, and had fewer difficulties in social situations. Adverse events were uncommon (5.5%), were mild, and did not require treatment. At study end, 53% of patients reported no dermatology-specific HRQOL impairment and 90% were satisfied with treatment. CONCLUSIONS: Significant, meaningful, rapid, and durable reductions in disease severity and functional impairment, as well as improvements in HRQOL, were seen following BoNT-A treatment. BoNT-A was safe and well tolerated, producing high levels of patient satisfaction. 相似文献
8.
9.
Douglas Wholey PhD ; Ira Moscovice PhD ; Terry Hietpas PharmD ; Jeremy Holtzman MD MS 《The Journal of rural health》2004,20(4):304-313
The environmental context of patient safety and medical errors was explored with specific interest in rural settings. Special attention was paid to unique features of rural: healthcare organizations and their environment that relate to the patient safety issue and medical errors (including the distribution of patients, types of adverse events associated with learning, information flows, triage and transfer decisions, and culture of safety). Relevant organizational theories and strategies fo medical error reduction and prevention in rural health care settings were identified. Financial and technical assistance are needed to support the systematic collection of data from rural hospitals and other entities and to enhance relevant patient safety practices for rural America. 相似文献
10.
James B. Harris MD Richard C. Ahrens MD Gary Milavetz PharmD Linda Annis Rebecca Ries BA Connie Hendricker RRT 《The Journal of allergy and clinical immunology》1990,85(6):1043-1049
Inhaled beta-agonists can produce bronchodilatation and reduce airway hyperreactivity in patients with asthma. Using these two measures, we compared inhaled bitolterol (three puffs, 1110 micrograms), albuterol (two puffs, 180 micrograms), and placebo administered by metered-dose inhaler in a blinded, crossover study of 40 subjects with chronic asthma. On each study day, subjects underwent histamine challenges at 1 1/2 hours before, and 1/2, 2, 4, 6, and 8 hours after inhaling one of the three test-drug treatments. Both drugs produced significant bronchodilatation at 30 minutes through 4 hours and significant effects on airway reactivity at 30 minutes through 2 hours (p less than 0.05). Bitolterol also produced small but significant bronchodilator effects at 6 hours and effects on airway reactivity at 4 hours (p less than 0.05). Effects of bitolterol on airway reactivity diminished significantly more slowly than effects of albuterol in subjects with baseline provocative concentration causing a 20% fall in FEV1 greater than or equal to 1.0 mg/ml of histamine (half-life of biologic effect 1.37 versus 0.92 hours; p less than 0.05) but not in subjects with baseline provocative concentration causing a 20% fall in FEV1 less than or equal to 1.0 mg/ml (half-life of biologic effect of 1.01 versus 1.00 hours; p greater than 0.05). 相似文献